[Graves' disease]

Area of Science:

• Endocrinology
• Immunology

Context:

• Graves' disease pathogenesis, particularly the role of TSH receptor antibodies, requires further elucidation.
• Current treatments for Graves' disease lack definitive superiority, necessitating exploration of predictive relapse markers.

Purpose:

• To review the current understanding of Graves' disease etiology and diagnosis.
• To discuss established and emerging therapeutic strategies for Graves' disease and its complications.
• To highlight the complexities of managing Graves' disease during pregnancy.

Summary:

• The genetic and environmental factors contributing to Graves' disease and TSH receptor antibody development are not fully understood.
• Antithyroid drugs are standard treatment, but predicting relapse for timely surgical or radiometabolic intervention is challenging.
• Graves' orbitopathy management involves severity assessment, with IV steroids for active cases and ongoing evaluation of new therapies.
• Pregnancy with Graves' disease demands a multidisciplinary approach, fetal monitoring, and cautious drug selection due to teratogenicity concerns, favoring propylthiouracil in early stages.

Impact:

• Improved understanding may lead to earlier diagnosis and more personalized treatment strategies for Graves' disease.
• Development of predictive markers could optimize the use of surgical or radiometabolic treatments.
• Enhanced management protocols for Graves' orbitopathy and pregnancy-related cases will improve patient outcomes.